The year 2025 marked a significant milestone in the field of geroscience, characterized by rapid advancements as well as notable challenges. Despite the multifaceted nature of progress—including both high points and stagnations—the overall trajectory remains promising. To gain deeper insights into the state of geroscience as 2025 concluded, we engaged five leading experts in the field. Their perspectives illuminate the breakthroughs, hurdles, and evolving dynamics anticipated in 2026.

Reflections on Progress and Challenges

Expert Insights on Geroscience in 2025

The following are reflections from prominent figures in geroscience regarding the most notable achievements and setbacks of the year:

Steve Horvath, Principal Investigator at Altos Labs

Geroscience made substantial strides, particularly in the integration of AI into aging biology. The emergence of models such as CpGPT signifies a transformative shift from traditional biomarkers to dynamically improving aging models. However, human rejuvenation trials, particularly plasmapheresis studies, were disappointing, highlighting the translational challenges in systemic interventions.

George Church, Professor at Harvard Medical School & MIT

Innovative targets for aging-reversal therapies progressed significantly, yet clinical trials for dietary supplements did not meet expectations due to underfunding. Nevertheless, multi-target research is gaining momentum, projecting a bright outlook for the field.

Andrea Maier, Professor in Medicine at the National University of Singapore

Precision in biological age measurement advanced remarkably, moving from theory to clinical applicability. However, intervention trials faced delays due to regulatory uncertainties surrounding phenotyping and aging endpoints. My long-term optimism remains unchanged, as precision interventions are emerging as the future of gerotherapeutics.

Matt Kaeberlein, CEO of Optispan

Public awareness of geroscience has drastically increased, with impactful dialogues occurring among policymakers and industry leaders. Nonetheless, traditional interventions such as rapamycin still dominate in efficacy, necessitating rigorous scientific inquiry to uncover new breakthroughs.

Oliver Medvedik, Chief Science Officer at Lifespan Research Institute

Interest in geroscience has exploded over the years, driven by breakthroughs in epigenetics and technology. However, we still lack interventions that significantly outperform dietary restriction methods for lifespan extension, underscoring the need for ongoing research.

Influential Contributions and Findings

Each expert identified pivotal works from 2025 that shaped their understanding of geroscience:

Steve Horvath:The study by Lei et al. demonstrated engineered cells' effectiveness in improving aging phenotypes in primates, substantially contributing to the field's knowledge.George Church:Advancements in specific therapeutic delivery mechanisms using AI-designed vectors could lead to significant improvements in lower-dose therapies.Andrea Maier:Guido Kroemer’s contribution provided a consensus on conceptualizing aging as a network-mediated process, urging a shift towards precision medicine.Matt Kaeberlein:The upcoming FDA approval for a geroscience-based intervention in veterinary medicine signals a new avenue for translational research.Oliver Medvedik:The emergence of organizations advocating for aging biomarkers marks a collective movement towards understanding biological aging.

Anticipating Future Challenges and Breakthroughs

Looking ahead to 2026, the experts expressed a mix of optimism and caution about the future prospects of geroscience:

  • Steve Horvath: Anticipates an acceleration of knowledge and breakthroughs resulting from large datasets and AI integration.
  • George Church: Expects a shift in regulatory landscapes, facilitating faster approval processes for novel therapies.
  • Andrea Maier: Envisions targeted therapies linked to biological age specificities becoming mainstream.
  • Matt Kaeberlein: Foresees the first FDA approvals for geroscience indications in companion animals as pivotal milestones.
  • Oliver Medvedik: Emphasizes the importance of defining “accelerated aging” as a disease category to streamline clinical trials.

Conclusion

The collective insights from these experts underscore both the promising future and the significant challenges that remain in the field of geroscience. While 2025 was marked by substantial progress, it also revealed the complexities involved in translating scientific findings into actionable therapeutic interventions. As the field evolves, ongoing dialogue and innovative approaches will be essential in overcoming barriers and realizing the full potential of geroscience.

About the Author

Arkadi Mazin is a well-established journalist specializing in the intersection of science and public policy. With a background in economics and international relations, Mazin explores the social implications of longevity and life extension. He advocates for prioritizing the discourse on life extension within the framework of modern civilization.

This article was prepared by the Lifespan Research Institute, a non-profit organization dedicated to equipping the public with scientific insights and updates in the field of geroscience. Your support enables the continuation of free access to vital information.

For further inquiries or contributions, please contact us at [email protected].